
ALT Prime Medicine - a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the first patient has been dosed in the Company’s global Phase 1/2 clinical trial of PM577a, an investigational in vivo Prime Editor for H1069Q-mutated Wilson disease. The milestone marks the initiation of the first clinical study of an in vivo Prime Editing therapy from Prime Medicine, as well as the first clinical evaluation of the company’s liver franchise. The company also announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to PM577 for Wilson disease.

ALT Prime medicine today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for PM647, an investigational in vivo Prime Editor for Alpha-1 Antitrypsin Deficiency (AATD). The clearance enables PM647 to proceed to clinical study initially in the United States, where approximately 100,000 people carry the PiZZ genotype that PM647 is designed to correct.


























